PATENT CLAIM ANALYSIS

Application Number: 16259913
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["544", "359000"]

Abstract:
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.

Claim (Index 16):
The compound of  claim 1 , wherein the compound is in the form of particles wherein at least 90% of the particles are greater than 0.01 microns and less than 500 microns.

Metadata:
- Claim Count in Document: 52.0
- Percentile: 99.0
- Lexical Diversity: 1.27778
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15918868', '14865370', '12970785', '15886104', '15150999']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7282383358478414
- 35 USC 102 Novelty (BERT): 0.5453077200248784
- Combined Prediction Score: 0.709945274265545
- Mean Citation Score: 289.889264
- Max Citation Score: 385.3687
- Similarity Product: 334.8190474494934

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test